S. Klang

Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.

Ariel Hammerman, John Hornberger, Julie Doberne, 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Variability in Outpatient Antimicrobial Consumption in Israel

I. Lavi, S. Klang, A. Hammerman, 2010, Infection.

Sensitivity, but Not Specificity, of a Quantitative Immunochemical Fecal Occult Blood Test for Neoplasia Is Slightly Increased by the Use of Low-Dose Aspirin, NSAIDS, and Anticoagulants

S. Klang, P. Rozen, Y. Niv, 2009, The American Journal of Gastroenterology.

Antipsychotics and Diabetes: An Age-Related Association

M. Goldfracht, S. Klang, A. Hammerman, 2008, The Annals of pharmacotherapy.

Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry

S. Shak, B. Uziely, J. Zidan, 2017, npj Breast Cancer.

The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients

S. Klang, N. Ben-Baruch, L. Soussan-Gutman, 2013, Breast Cancer Research and Treatment.

A prospective study of the impact of the 21-gene recurrence score assay on treatment decisions in N-, ER+ early stage breast cancer patients

S. Klang, A. Hammerman, N. Liebermann, 2007 .

Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry

S. Shak, B. Uziely, J. Zidan, 2017, npj Breast Cancer.

PCN57 TRASTUZUMAB USE FOR METASTATIC BREAST CANCER–IS “MEDIAN TIME TO TREATMENT FAILURE” AN ACCURATE PARAMETER FOR BUDGET IMPACT ANALYSIS?

S. Klang, A. Hammerman, N. Liebermann, 2006 .

Evaluation of recurrence score and traditional clinicopathologic metrics in a large ER-positive, lymph node-negative patient cohort.

S. Shak, F. Baehner, C. Yoshizawa, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of recurrence score and traditional clinicopathologic assessments in a large ER-positive, lymph node-negative patient cohort.

S. Shak, F. Baehner, C. Yoshizawa, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.